Ionis Pharmaceuticals (IONS) Cash & Equivalents (2009 - 2026)

Ionis Pharmaceuticals' Cash & Equivalents history runs 18 years deep, the most recent figure standing at $173.4 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 34.37% year-over-year to $173.4 million; the TTM figure through Mar 2026 stood at $173.4 million (down 34.37% YoY), while the FY2025 annual figure was $372.3 million, up 53.78% from the prior year.
• Cash & Equivalents was $173.4 million for Q1 2026 at Ionis Pharmaceuticals, down from $372.3 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $542.5 million in Q1 2022 to a low of $173.4 million in Q1 2026.
• Historically, Cash & Equivalents has averaged $341.5 million across 5 years, with a median of $334.6 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Cash & Equivalents sank 68.19% in 2022, then surged 53.78% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $276.5 million in 2022, then soared by 44.41% to $399.3 million in 2023, then slumped by 39.37% to $242.1 million in 2024, then soared by 53.78% to $372.3 million in 2025, then plunged by 53.42% to $173.4 million in 2026.
• The last three Cash & Equivalents figures came in at $173.4 million (Q1 2026), $372.3 million (Q4 2025), and $338.3 million (Q3 2025), per Business Quant data.